Table 1:
Patient and Transplant Characteristics at time of 1st transplant
| Total N= 232 | |
|---|---|
| Characteristics at time of first HCT | |
| Age, median (range) in months | 10.9 (0.5–20.9) |
| Interval from diagnosis to HCT(Months), median (range) | 11 (0.5–141.6) |
| N (%) | |
| Gender Male:Female | 98 (42.2%) : 134 (57.8%) |
| Diagnosis | |
| ALL | 121 (52.2%) |
| AML | 98 (42.2%) |
| MDS | 13 (5.6%) |
| Disease Phase | |
| ALL CR1 | 15 (6.5%) |
| ALL CR2 | 52 (22.4%) |
| ALL advanced | 54 (23.3%) |
| AML CR1 | 34 (14.7%) |
| AML CR2 | 14 (6.0%) |
| AML advanced | 49 (21.1%) |
| MDS | 14 (6.0%) |
| Leukemia burden at HCT | |
| Pre-MRD era | 36 (15.5%) |
| Blasts>=25% | 50 (21.6%) |
| Blasts 0–24% | 80 (34.5%) |
| MRD positive | 17 (7.3%) |
| MRD negative | 47 (20.3%) |
| EMD only | 2 (0.9%) |
| Transplant Characteristics | |
| Decade of HCT | |
| 1990–2000 | 140 (60.3%) |
| 2001–2011 | 92 (39.7%) |
| Donor Type | |
| Matched Related | 79 (34.1%) |
| Unrelated Marrow/PB | 105 (45.3%) |
| Cord/Other Donor | 48 (20.7%) |
| Conditioning Regimen | |
| RIC | 11 (4.7%) |
| Chemo-based myeloablative | 23 (9.9%) |
| TBI-based | 198 (85.3%) |
| TBI dose (Gy) | |
| 2 | 2 (1.0%) |
| 12 | 31 (15.3%) |
| 13.2 | 72 (35.6%) |
| 14.4 | 74 (36.6%) |
| 15.75 | 23 (11.4%) |
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BU, busulfan; CR, complete remission; EMD, extra-medullary disease; MDS, myelodysplastic syndrome; MRD, minimal residual disease; PB, peripheral blood; RIC, reduced intensity conditioning; TBI, total body irradiation.